Last reviewed · How we verify
NCT06713161: NIR-II
Tumor-Targeted-NIR-II Fluorescent Molecular Probes for the Identification of Breast Cancer Tissue and SLN Metastatic Status
trial testing NIR-II Probe(i.e ICG-POL6326) incubation solution in Breast Cancer in 40 participants. Currently enrolling.
25 August 2025
Quick facts
| Lead sponsor | Yunnan Cancer Hospital |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 40 |
| Start date | 1 September 2024 |
| Primary completion | 25 August 2025 |
| Estimated completion | 25 December 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- NIR-II Probe(i.e ICG-POL6326) incubation solution
Conditions studied
- Breast Cancer — all drugs for Breast Cancer →
- Sentinel Lymph Node — all drugs for Sentinel Lymph Node →
- Metastases — all drugs for Metastases →
- Margin Assessment — all drugs for Margin Assessment →
Sponsor
Yunnan Cancer Hospital
Who can join
Adults 18 to 75, female only, with Breast Cancer or Sentinel Lymph Node. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Accurate evaluation of tumor boundaries in breast-conserving surgery is closely associated with reducing the second operation of patients. Meanwhile, accurately assessing sentinel lymph node (SLN) metastasis is crucial for determining the extent of axillary lymph node dissection (ALND) and minimizing complications. Near-infrared-II (NIR-II) fluorescence imaging using molecular agents has shown promise for in situ imaging during resection. However, very effective probes can be applied to clinical trials up to now, which limits the clinical application of fluorescence imaging. Here we developed a new technology that can quickly differentiation between cancer and para-cancer tissue as well as metastatic and normal sentinel lymph nodes(SLN). In brief, the fresh tissues were incubated with the probe immediately after intraoperative resection and imaged to identify the tumor area and distinguish the metastatic status of SLN. The accuracy of fluorescence imaging was confirmed by pathological diagnosis.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06713161
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Breast Cancer
Currently open trials in the same condition.
- NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
- NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
- NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
- NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
- NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting
Other Yunnan Cancer Hospital trials
Trials by the same sponsor.
- NCT07018505 — EpCAM-Targeted Surface-Enhanced Raman Spectroscopy Nanotags for Rapid Evaluation of Surgical Margins and Sentinel Lymph · not yet recruiting
- NCT06977386 — The Application Value of Spectral CT in the Accurate Staging of Gastric Cancer · NA · not yet recruiting
- NCT06977399 — The Application Value of Spectral CT in the Accurate Staging of Liver Cancer · NA · not yet recruiting
- NCT06977373 — The Application Value of Spectral CT in the Accurate Staging of Colorectal Cancer · NA · not yet recruiting
- NCT06977412 — The Application Value of Spectral CT in the Accurate Staging of Breast Cancer · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06713161 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Yunnan Cancer Hospital
- Last refreshed: 3 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06713161.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing